<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04875949</url>
  </required_header>
  <id_info>
    <org_study_id>DISAUT-AB ICH</org_study_id>
    <nct_id>NCT04875949</nct_id>
  </id_info>
  <brief_title>Anti-Cholinergic Receptors Antibodies, Autonomic Profile and Dysautonomia Symptoms in PAF, ALS and POTS (DISAUT-AB)</brief_title>
  <acronym>DISAUT-AB</acronym>
  <official_title>Anti-Cholinergic Receptors Antibodies and Dysautonomia Symptoms Relationships in Pure Autonomic Failure, Amyotrophic Lateral Sclerosis, Postural Orthostatic Tachycardia Syndrome: a Pathophysiology Based Therapeutic New Strategy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondazione Salvatore Maugeri</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anti alfa-3 and alfa-7 ganglionic cholinergic receptors (anti-AChRs) antibodies (Abs) plasma&#xD;
      removal by plasmapheresis (1,2) acutely improved dysautonomia symptoms in case reports with&#xD;
      Pure Autonomic Failure (PAF) (3). We shall assess the prevalence of anti-AChRs Ab and the&#xD;
      relationship among Ab titer, cardiovascular autonomic profile and symptoms in&#xD;
      neurodegenerative diseases characterized by similar dysautonomia symptoms such as PAF,&#xD;
      Amyotrophic Lateral Sclerosis (ALS) and Postural Orthostatic Tachycardia Syndrome (POTS) (4).&#xD;
      Ab positive patients will undergo selective immunoabsorption once a week up to achievement of&#xD;
      Ab titer lower than 65% of baseline followed by immunosuppressive therapy with prednisone.&#xD;
      Both Ab positive and negative groups will undergo anti-AChR Abs, autonomic profile and&#xD;
      dysautonomia symptoms assessment, every 4 months up to 3 years. Evidence of correlation among&#xD;
      reduced Ab titer and autonomic profile and symptoms improvement may result in new effective&#xD;
      therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PAF is a rare neurodegenerative disorder characterized by symptoms due to sympathetic&#xD;
      failure, such as orthostatic hypotension and syncope, and deficient parasympathetic activity&#xD;
      such as constipation, urinary retention and decreased salivation (3). Plasma anti-AChRs Abs&#xD;
      were found in PAF (1, 2, 5) and in POTS (6), raising the possibility that Ab mediated&#xD;
      alterations in the ganglionic cholinergic function might induce autonomic abnormalities and&#xD;
      related symptoms. Anti-AchRs Abs removal by plasmapheresis was associated with acute&#xD;
      improvement of orthostatic tolerance in PAF single case report (2).&#xD;
&#xD;
      There is no data on the medium/long term clinical follow-up of these patients. Nothing is&#xD;
      known about the time course of the relationships among Abs plasma titer, neural autonomic&#xD;
      profile and symptoms if a selective immunoabsorption procedure is combined with drug&#xD;
      immunosoppression (Prednisone) to lower Ab levels and potentially ameliorate ganglionic&#xD;
      function.&#xD;
&#xD;
      Finally, it is unknown whether a neurodegenerative disease with concomitant dysautonomia&#xD;
      symptoms such as the Amyotrophic Lateral Sclerosis (ALS) may share an analogous anti-AChRs Ab&#xD;
      profile. Variations in cholinergic receptor subunits 3 and 4 were observed in ALS but no&#xD;
      plasma anti-AChRs Abs were searched for (7). Abs removal by immunoabsorption technique&#xD;
      combined with drug immunosoppression might represent a new effective therapy for dysautonomia&#xD;
      symptoms in ALS as well as in POTS and PAF.&#xD;
&#xD;
      Hyphotesis and Significance:&#xD;
&#xD;
        -  Changes in anti-AChR Abs plasma titer may be mirrored by modifications in the&#xD;
           cardiovascular autonomic profile, as assessed by spectrum analysis of RR and arterial&#xD;
           pressure variability, and be related to fluctuations in the magnitude of dysautonomia&#xD;
           symptoms in PAF, ALS and POTS patients.&#xD;
&#xD;
        -  Plasma anti-AChR Abs might underlie dysautonomia symptoms associated to&#xD;
           neurodegenerative disorders such as ASL and POTS&#xD;
&#xD;
        -  Plasma anti-AChR Abs removal by selective immunoabsorption techniques may improve&#xD;
           ganglionic transmission leading to clinical amelioration and represent a new effective&#xD;
           etiologic therapy for these diseases.&#xD;
&#xD;
      Specific Aim:&#xD;
&#xD;
      Aim 1: To evaluate the prevalence of plasma anti-AChR Abs in patients affected by PAF, ALS&#xD;
      and POTS .&#xD;
&#xD;
      Aim 2: To address the time course and relationships of anti-AChR Abs plasma titers,&#xD;
      cardiovascular autonomic profile and dysautonomia symptoms before and after anti-AChR Abs&#xD;
      plasma removal by selective immunoabsorption technique in PAF, ALS and POTS patients. The&#xD;
      core laboratory of the Neuroimmunology Unit of Istituto Neurologico Besta will provide&#xD;
      expertise and facilities for assessing plasma anti-AChR Abs. The clinical laboratory of&#xD;
      Clinica Medica Syncope Unit (Humanitas) will provide the know-how and facilities for patients&#xD;
      neural autonomic assessment.&#xD;
&#xD;
      Aim 3:To set up a new therapeutic strategy based on selective immunoabsorption technique&#xD;
      sessions combined with drug immunosuppression (Prednisone) in patients with anti-AChR Abs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">April 2019</completion_date>
  <primary_completion_date type="Actual">January 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of plasma anti-AChR Abs in PAF, ALS and POTS</measure>
    <time_frame>3 years</time_frame>
    <description>Number of patients with plasma anti-AChR Abs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effects of anti-AChR Abs removal on dysautonomic symptoms</measure>
    <time_frame>3 years</time_frame>
    <description>COMPASS31 scores (range 0-100; 0 best -100 worst)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time course of dysautonomia symptoms</measure>
    <time_frame>3 years</time_frame>
    <description>COMPASS31 scores (range: 0-100; 0 best-100 worst)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time course of orthostatic tolerance</measure>
    <time_frame>3 years</time_frame>
    <description>Orthostatic tolerance (minutes)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Pure Autonomic Failure</condition>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <condition>Postural Orthostatic Tachycardia Syndrome</condition>
  <condition>Anti-Cholinergic Receptors Antibodies</condition>
  <arm_group>
    <arm_group_label>Anti-AChRs Abs positive patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immunoabsorption</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Immunoabsorption/plasmapheresis procedure</intervention_name>
    <arm_group_label>Anti-AChRs Abs positive patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        • Patients, older than 18 years affected by PAF, ALS and POTS, with dysautonomia symptoms&#xD;
        assessed by clinical evaluation and by the Composite Autonomic Scoring Scale (CASS)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hepatic, renal, heart and other secondary causes of autonomic dysfunction&#xD;
&#xD;
          -  History/familiarity with seizures&#xD;
&#xD;
          -  Atrial fibrillation and other relevant cardiac rhythm disturbances&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Other neurological or psychiatric diseases&#xD;
&#xD;
          -  Pacemakers or other electronic implants inserted into the body&#xD;
&#xD;
          -  Coronary disorders, elevated intracranial blood pressure&#xD;
&#xD;
          -  Assumption of drugs facilitating seizures, psychiatric drugs, alcohol abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raffaello Furlan, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Humanitas Research Hospital, Humanitas University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Franca Barbic, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Humanitas Research Hospital, Humanitas University, Rozzano</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raffaello Furlan, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Humanitas Research Hospital, Humanitas University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Humanitas Research Hospital</name>
      <address>
        <city>Rozzano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Vernino S, Low PA, Fealey RD, Stewart JD, Farrugia G, Lennon VA. Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies. N Engl J Med. 2000 Sep 21;343(12):847-55.</citation>
    <PMID>10995864</PMID>
  </reference>
  <reference>
    <citation>Schroeder C, Vernino S, Birkenfeld AL, Tank J, Heusser K, Lipp A, Benter T, Lindschau C, Kettritz R, Luft FC, Jordan J. Plasma exchange for primary autoimmune autonomic failure. N Engl J Med. 2005 Oct 13;353(15):1585-90.</citation>
    <PMID>16221781</PMID>
  </reference>
  <reference>
    <citation>Furlan R, Jacob G, Snell M, Robertson D, Porta A, Harris P, Mosqueda-Garcia R. Chronic orthostatic intolerance: a disorder with discordant cardiac and vascular sympathetic control. Circulation. 1998 Nov 17;98(20):2154-9.</citation>
    <PMID>9815870</PMID>
  </reference>
  <reference>
    <citation>Vernino S, Hopkins S, Wang Z. Autonomic ganglia, acetylcholine receptor antibodies, and autoimmune ganglionopathy. Auton Neurosci. 2009 Mar 12;146(1-2):3-7. doi: 10.1016/j.autneu.2008.09.005. Epub 2008 Oct 31. Review.</citation>
    <PMID>18951069</PMID>
  </reference>
  <reference>
    <citation>Sabatelli M, Eusebi F, Al-Chalabi A, Conte A, Madia F, Luigetti M, Mancuso I, Limatola C, Trettel F, Sobrero F, Di Angelantonio S, Grassi F, Di Castro A, Moriconi C, Fucile S, Lattante S, Marangi G, Murdolo M, Orteschi D, Del Grande A, Tonali P, Neri G, Zollino M. Rare missense variants of neuronal nicotinic acetylcholine receptor altering receptor function are associated with sporadic amyotrophic lateral sclerosis. Hum Mol Genet. 2009 Oct 15;18(20):3997-4006. doi: 10.1093/hmg/ddp339. Epub 2009 Jul 23.</citation>
    <PMID>19628475</PMID>
  </reference>
  <reference>
    <citation>Vernino S, Adamski J, Kryzer TJ, Fealey RD, Lennon VA. Neuronal nicotinic ACh receptor antibody in subacute autonomic neuropathy and cancer-related syndromes. Neurology. 1998 Jun;50(6):1806-13.</citation>
    <PMID>9633732</PMID>
  </reference>
  <reference>
    <citation>Furlan R, Piazza S, Bevilacqua M, Turiel M, Norbiato G, Lombardi F, Malliani A. Pure Autonomic Failure: complex abnormalities in the neural mechanisms regulating the cardiovascular system. J Auton Nerv Syst. 1995 Mar 2;51(3):223-35.</citation>
    <PMID>7769156</PMID>
  </reference>
  <reference>
    <citation>Barbic F, Perego F, Canesi M, Gianni M, Biagiotti S, Costantino G, Pezzoli G, Porta A, Malliani A, Furlan R. Early abnormalities of vascular and cardiac autonomic control in Parkinson's disease without orthostatic hypotension. Hypertension. 2007 Jan;49(1):120-6. Epub 2006 Nov 13.</citation>
    <PMID>17101845</PMID>
  </reference>
  <reference>
    <citation>Porta A, Castiglioni P, Di Rienzo M, Bari V, Bassani T, Marchi A, Takahashi AC, Tobaldini E, Montano N, Catai AM, Barbic F, Furlan R, Cividjian A, Quintin L. Short-term complexity indexes of heart period and systolic arterial pressure variabilities provide complementary information. J Appl Physiol (1985). 2012 Dec 15;113(12):1810-20. doi: 10.1152/japplphysiol.00755.2012. Epub 2012 Oct 25.</citation>
    <PMID>23104699</PMID>
  </reference>
  <reference>
    <citation>Furlan R, Porta A, Costa F, Tank J, Baker L, Schiavi R, Robertson D, Malliani A, Mosqueda-Garcia R. Oscillatory patterns in sympathetic neural discharge and cardiovascular variables during orthostatic stimulus. Circulation. 2000 Feb 29;101(8):886-92.</citation>
    <PMID>10694528</PMID>
  </reference>
  <reference>
    <citation>Barbic F, Galli M, Dalla Vecchia L, Canesi M, Cimolin V, Porta A, Bari V, Cerri G, Dipaola F, Bassani T, Cozzolino D, Pezzoli G, Furlan R. Effects of mechanical stimulation of the feet on gait and cardiovascular autonomic control in Parkinson's disease. J Appl Physiol (1985). 2014 Mar 1;116(5):495-503. doi: 10.1152/japplphysiol.01160.2013. Epub 2014 Jan 16.</citation>
    <PMID>24436294</PMID>
  </reference>
  <reference>
    <citation>Low PA. Composite autonomic scoring scale for laboratory quantification of generalized autonomic failure. Mayo Clin Proc. 1993 Aug;68(8):748-52.</citation>
    <PMID>8392653</PMID>
  </reference>
  <reference>
    <citation>Chiò A, Mora G, Restagno G, Brunetti M, Ossola I, Barberis M, Ferrucci L, Canosa A, Manera U, Moglia C, Fuda G, Traynor BJ, Calvo A. UNC13A influences survival in Italian amyotrophic lateral sclerosis patients: a population-based study. Neurobiol Aging. 2013 Jan;34(1):357.e1-5. doi: 10.1016/j.neurobiolaging.2012.07.016. Epub 2012 Aug 22.</citation>
    <PMID>22921269</PMID>
  </reference>
  <reference>
    <citation>Chiò A, Calvo A, Moglia C, Mazzini L, Mora G; PARALS study group. Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry. 2011 Jul;82(7):740-6. doi: 10.1136/jnnp.2010.235952. Epub 2011 Mar 14.</citation>
    <PMID>21402743</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 12, 2021</study_first_submitted>
  <study_first_submitted_qc>May 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2021</study_first_posted>
  <last_update_submitted>May 3, 2021</last_update_submitted>
  <last_update_submitted_qc>May 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neural control of circulation and respiration</keyword>
  <keyword>Anti-Cholinergic receptors antibodies</keyword>
  <keyword>Power Spectrum Analysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Pure Autonomic Failure</mesh_term>
    <mesh_term>Primary Dysautonomias</mesh_term>
    <mesh_term>Postural Orthostatic Tachycardia Syndrome</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

